Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Problems associated with switch to modafinil - a novel alerting agent in narcolepsy EUROPEAN JOURNAL OF NEUROLOGY Guilleminault, C., Aftab, F. A., Karadeniz, D., Philip, P., Leger, D. 2000; 7 (4): 381-384

Abstract

Modafinil is a novel medication recently approved for the treatment of narcolepsy and idiopathic hypersomnia. Commonly, patients had already been prescribed medications for their syndrome. This report outlines difficulties encountered in the clinical practice of switching patients to modafinil. Naïve subjects accepted modafinil best. Subjects withdrawn from amphetamine had the most problems and failure to withdraw. Venlafaxine hydrochloride combined well with modafinil to control cataplectic attacks. Usage of a progressive withdrawal protocol may ease the difficulties observed.

View details for Web of Science ID 000088697000002

View details for PubMedID 10971596